7月2日 - ** Arcturus Therapeutics（ARCT.O）股价在盘前交易中上涨5.8%，至7.29美元
** 该公司宣布与赛默飞世尔科技（TMO.N）达成合作，以支持其用于治疗囊性纤维化的实验性mRNA疗法ARCT-032的潜在后期 开发及商业化
** 囊性纤维化是一种遗传性疾病，主要影响肺部和消化系统
** TMO将为该项目提供生产、临床研究及商业化准备服务，ARCT称。
** 若中期试验数据积极，ARCT计划通过TMO的临床研究业务开展其后期临床项目
** 若ARCT-032获批，TMO将获得独家商业化生产权，ARCT称。
** 截至上一交易日收盘，ARCT今年以来累计上涨12.4%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.